Shares of Repligen Corp. (NASDAQ:RGEN) shot up 4.2% on Thursday . The company traded as high as $30.75 and last traded at $30.73, with a volume of 103,177 shares. The stock had previously closed at $29.49.

A number of research firms have weighed in on RGEN. Zacks Investment Research raised shares of Repligen Corp. from a “sell” rating to a “hold” rating in a report on Thursday. Jefferies Group reissued a “hold” rating and set a $28.00 price objective on shares of Repligen Corp. in a report on Monday, June 13th.

The company’s 50-day moving average price is $27.85 and its 200 day moving average price is $25.82. The firm has a market cap of $1.05 billion and a price-to-earnings ratio of 124.52.

Repligen Corp. (NASDAQ:RGEN) last posted its earnings results on Thursday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.03. The business had revenue of $29.20 million for the quarter, compared to analyst estimates of $24.75 million. During the same period last year, the company posted $0.11 EPS. The firm’s revenue for the quarter was up 35.8% compared to the same quarter last year. Equities analysts predict that Repligen Corp. will post $0.44 earnings per share for the current fiscal year.

In related news, Director Thomas F. Ryan, Jr. sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $24.59, for a total transaction of $245,900.00. Following the completion of the sale, the director now owns 27,094 shares of the company’s stock, valued at approximately $666,241.46. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 5,000 shares of the stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $26.60, for a total transaction of $133,000.00. Following the sale, the director now directly owns 12,094 shares of the company’s stock, valued at approximately $321,700.40. The disclosure for this sale can be found here.

A number of hedge funds have bought and sold shares of RGEN. California State Teachers Retirement System increased its stake in Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock worth $1,722,000 after buying an additional 984 shares during the period. Rhumbline Advisers increased its stake in Repligen Corp. by 9.4% in the fourth quarter. Rhumbline Advisers now owns 57,619 shares of the company’s stock worth $1,630,000 after buying an additional 4,970 shares during the period. Russell Frank Co increased its stake in Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock worth $1,933,000 after buying an additional 7,498 shares during the period. Principal Financial Group Inc. increased its stake in Repligen Corp. by 4.7% in the fourth quarter. Principal Financial Group Inc. now owns 216,985 shares of the company’s stock worth $6,139,000 after buying an additional 9,758 shares during the period. Finally, Globeflex Capital L P increased its stake in Repligen Corp. by 50.6% in the fourth quarter. Globeflex Capital L P now owns 36,153 shares of the company’s stock worth $1,023,000 after buying an additional 12,153 shares during the period.

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.